Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Addyi, Rejects Gender Discrimination Claims

This article was originally published in RPM Report

Executive Summary

FDA knew its decision on whether to approve the first treatment for female sexual dysfunction would be controversial. The Division Director's memo explaining the decision and acknowledging the controversy makes for interesting reading.

You may also be interested in...



Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed

Advisory committee votes 18-6 to recommend approval of the female sexual dysfunction drug contingent on a risk management plan, despite unease about modest efficacy and risks such as fainting.

A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.

The Future Of Purdue: Will The ‘Public Benefit Corporation’ Model Take Off?

Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a public benefit company could have far-reaching significance for the industry – if it ever gets off the ground.

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel